ClinicalTrials.Veeva

Menu

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (Umbriel)

AstraZeneca logo

AstraZeneca

Status and phase

Begins enrollment this month
Phase 2

Conditions

Asthma

Treatments

Drug: Placebo
Drug: Tozorakimab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06890351
2024-519116-14-00 (Registry Identifier)
D9181C00002

Details and patient eligibility

About

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Enrollment

540 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Provision of signed and dated written informed consent prior to any study-specific procedures.

  2. Adults aged 18-75, inclusive when signing the informed consent.

  3. Documented physician-diagnosis of asthma for at least 12 months.

  4. Treated with medium or high dose ICS in combination with LABA.

  5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 .

  6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal.

  7. Documented exacerbation history in the last 12 months and biomarker requirements of:

    1. 2 severe exacerbations OR
    2. 1 severe exacerbation and:

    (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb

  8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary.

  9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test.

  10. Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

  1. Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1.
  2. Clinically significant pulmonary disease other than asthma .
  3. Current smokers, former smokers with >10 pack-years history.
  4. Clinically significant aortic stenosis or pulmonary arterial hypertension.
  5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease.
  6. Unstable cardiovascular disorders.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

540 participants in 3 patient groups, including a placebo group

Tozorakimab Dose 1
Experimental group
Description:
Dosing subcutaneously tozorakimab Dose 1
Treatment:
Drug: Tozorakimab
Tozorakimab Dose 2
Experimental group
Description:
Dosing subcutaneously tozorakimab Dose 2 and placebo
Treatment:
Drug: Tozorakimab
Placebo
Placebo Comparator group
Description:
Dosing subcutaneously with equivalent volume to tozorakimab
Treatment:
Drug: Placebo

Trial contacts and locations

151

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems